Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (5), 567-576

Preservation of Ovarian Function and Fertility Despite Gonadotoxic Chemotherapy


Preservation of Ovarian Function and Fertility Despite Gonadotoxic Chemotherapy

Zeev Blumenfeld. Expert Rev Endocrinol Metab.


The author aims to review the various strategies and avenues for fertility preservation despite gonadotoxic chemotherapy in young women. The recent increase in the survival of young patients has increased the worldwide attempts toward fertility preservation. The currently utilized methods are sperm cryopreservation and banking in male patients, and cryopreservation of embryos, unfertilized oocytes and ovarian tissue, as well as administration of gonadotropin-releasing hormone agonists (GnRH-a) before and during the gonadotoxic chemotherapy in young female patients. For those patients in whom pelvic irradiation is planned, ovariopexy is suggested. Since none of the suggested methods are ideal and none guarantees future fertility, a combination of several methods may optimize patients' chance of fertility preservation. GnRH-a co-treatment may reduce ovarian damage significantly in female patients treated with gonadotoxic chemotherapy. GnRH-a should be considered for women of reproductive age receiving gonadotoxic chemotherapy in addition to assisted reproduction and cryopreservation of embryos, oocytes and ovarian tissue.

Keywords: GnRH agonist; chemotherapy; fertility preservation; gonadotoxicity; premature ovarian failure.

Similar articles

See all similar articles

Cited by 1 article

LinkOut - more resources